Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00241_DB01418_nanopub.RA21Z8GxGOqywsT-43iDsQdCFMbbiOJZkwaP-pznbPIeI#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00241_DB01418 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00241_DB01418 label "DDI between Butalbital and Acenocoumarol - Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. [drugbank_resource:DB00241_DB01418]" assertion.
- drugbank_resource:DB00241_DB01418 identifier "drugbank_resource:DB00241_DB01418" assertion.
- drugbank_resource:DB00241_DB01418 title "DDI between Butalbital and Acenocoumarol - Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes." assertion.
- drugbank:DB01418 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB01418 assertion.
- drugbank:DB00241 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB01418 assertion.